Molecular heterogeneity in adjacent cells in triple-negative breast cancer

Código QR

Molecular heterogeneity in adjacent cells in triple-negative breast cancer

Michael L Huebschman,1 Nancy L Lane,1 Huaying Liu,1 Venetia R Sarode,2 Judith L Devlin,1 Eugene P Frenkel1,3 1Harold C Simmons Comprehensive Cancer Center, 2Department of Pathology, 3Division of Hematology-Medical Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Huebschman ML, Lane NL, Liu HY, Sarode VR, Devlin JL, Frenkel EP
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c8f3f56a3d4d4a618a5bb1edc5ff5b8a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

A triple negative breast cancer: what it is not!
por: Katakkar SB
Publicado: (2012)

Triple negative breast cancer: an Indian perspective
por: Akhtar M, et al.
Publicado: (2015)

Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
por: Marina K. Ibragimova, et al.
Publicado: (2021)

Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer
por: Paolo Peterlongo, et al.
Publicado: (2021)

Co-dependency for MET and FGFR1 in basal triple-negative breast cancers
por: Vanessa Y. C. Sung, et al.
Publicado: (2021)

Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer
por: Corey Speers, et al.
Publicado: (2017)

A DNA methylation-based liquid biopsy for triple-negative breast cancer
por: Katrina Cristall, et al.
Publicado: (2021)

RIPK1 is a negative mediator in Aquaporin 1-driven triple-negative breast carcinoma progression and metastasis
por: Zhuming Yin, et al.
Publicado: (2021)

Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
por: Xupeng Bai, et al.
Publicado: (2021)

Antiangiogenic therapy for breast cancer with triple negative phenotype
por: Inna P. Ganshina, et al.
Publicado: (2021)

Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
por: Hanne Vos, et al.
Publicado: (2021)

Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
por: Nina Radosevic-Robin, et al.
Publicado: (2021)

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
por: Otto Metzger-Filho, et al.
Publicado: (2021)

The LINC01119-SOCS5 axis as a critical theranostic in triple-negative breast cancer
por: Zhenbo Tu, et al.
Publicado: (2021)

Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis
por: Sixten Harborg, et al.
Publicado: (2021)

Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer
por: Craig Davison, et al.
Publicado: (2021)

Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer
por: Maitri Kalra, et al.
Publicado: (2021)

Locoregional recurrence of triple-negative breast cancer: effect of type of surgery and adjuvant postoperative radiotherapy
por: Bayoumi Y, et al.
Publicado: (2014)

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women
por: Vinayak W Patil, et al.
Publicado: (2011)

Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
por: da Silva JL, et al.
Publicado: (2021)

Opportunities for metastatic triple negative breast cancer therapy
por: Inna P. Ganshina, et al.
Publicado: (2021)

Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
por: Leisha A Emens, et al.
Publicado: (2021)

Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome
por: Juliana C. Wortman, et al.
Publicado: (2021)

Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study
por: Romualdo Barroso-Sousa, et al.
Publicado: (2021)

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
por: Fleisher B, et al.
Publicado: (2016)

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Julia Foldi, et al.
Publicado: (2021)

Correction: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Publicado: (2021)

Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients
por: Yves Boucher, et al.
Publicado: (2021)

Metabolic reprogramming underlies metastatic potential in an obesity-responsive murine model of metastatic triple negative breast cancer
por: Ciara H. O’Flanagan, et al.
Publicado: (2017)

Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer
por: Wei-Gang Qiu, et al.
Publicado: (2017)

Systemic immune reaction in axillary lymph nodes adds to tumor-infiltrating lymphocytes in triple-negative breast cancer prognostication
por: Fangfang Liu, et al.
Publicado: (2021)

Oseltamivir phosphate monotherapy ablates tumor neovascularization, growth, and metastasis in mouse model of human triple-negative breast adenocarcinoma
por: Haxho F, et al.
Publicado: (2014)

Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer
por: Jeffrey P. Solzak, et al.
Publicado: (2017)

Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
por: Huicheng Liu, et al.
Publicado: (2021)

Triple-negative breast cancer: treatment challenges and solutions
por: Collignon J, et al.
Publicado: (2016)

Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
por: Linda T. Vahdat, et al.
Publicado: (2021)

Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy
por: Maria Vittoria Dieci, et al.
Publicado: (2021)

MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer
por: Kwok-Kin Wong, et al.
Publicado: (2021)

Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
por: Inna P. Ganshina, et al.
Publicado: (2021)

Correction: MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer
Publicado: (2021)